Implant Sciences' QS-B220 Receives Regulatory Approval for China Airports and Civil Aviation Industry
- Explosives and drugs trace detection system continues regulatory testing success started in the U.S. and Europe
Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today its QS-B220 desktop explosives and drugs trace detector has received approval from the Civil Aviation Administration of China (CAAC).
"We are proud to have received approval for the QS-B220 from CAAC, which is the equivalent of the TSA in the United States. China has traditionally been a very strong market for us, with hundreds of our trace detection systems being currently used by police, airports, and subways. We believe our reputation for quality and performance will translate into significant QS-B220 sales in the Chinese market," stated Implant Sciences' CEO, Glenn D. Bolduc. "The QS-B220 is the only trace ETD in the world to currently have passed testing by the TSA in the United States, ECAC in Europe, and CAAC in China."
Drone Payload Market - Global Forecast to 2021
146 airports in China recently received $196 million in subsidies from the Civil Aviation Administration of China earlier in December 2014. According to the Chinese government's 12th five-year plan, the total number of airports is set to expand from 175 in 2010 to 230 in 2015.
About the QS-B220 Desktop Explosives and Drugs Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source : Implant Sciences Corporation - view original press release
May 24 - 25, 2017 - London, United Kingdom